[go: up one dir, main page]

AR059005A1 - Virus quimericos del dengue - Google Patents

Virus quimericos del dengue

Info

Publication number
AR059005A1
AR059005A1 ARP070100151A ARP070100151A AR059005A1 AR 059005 A1 AR059005 A1 AR 059005A1 AR P070100151 A ARP070100151 A AR P070100151A AR P070100151 A ARP070100151 A AR P070100151A AR 059005 A1 AR059005 A1 AR 059005A1
Authority
AR
Argentina
Prior art keywords
chemical
dengue viruses
viruses
dengue
chimeric
Prior art date
Application number
ARP070100151A
Other languages
English (en)
Original Assignee
Sanofi Pasteur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Pasteur filed Critical Sanofi Pasteur
Publication of AR059005A1 publication Critical patent/AR059005A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • C12N9/127—RNA-directed RNA polymerase (2.7.7.48), i.e. RNA replicase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Virus del dengue quiméricos que son menos propensos a acumular mutaciones puntuales y variaciones genéticas. En estos virus del dengue quiméricos, el gen de NS5, que codifica la polimerasa, ha sido reemplazado por la secuencia NS5 correspondiente de un virus de la fiebre amarilla. Composiciones inmunogénicas para uso farmacéutico.
ARP070100151A 2006-01-13 2007-01-12 Virus quimericos del dengue AR059005A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US86370806P 2006-01-13 2006-01-13

Publications (1)

Publication Number Publication Date
AR059005A1 true AR059005A1 (es) 2008-03-05

Family

ID=37814398

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070100151A AR059005A1 (es) 2006-01-13 2007-01-12 Virus quimericos del dengue

Country Status (6)

Country Link
US (2) US7968102B2 (es)
EP (1) EP1974023B1 (es)
JP (1) JP2009523019A (es)
AR (1) AR059005A1 (es)
CA (1) CA2633005C (es)
WO (1) WO2007093472A1 (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2909286B1 (fr) * 2006-12-01 2012-06-08 Sanofi Pasteur Methode d'immunisation contre les 4 serotypes de la dengue
AU2010286368B2 (en) * 2009-08-31 2015-09-03 Gen-Probe Incorporated Dengue virus assay
EP2877207A1 (en) * 2012-07-24 2015-06-03 Sanofi Pasteur Vaccine compositions for prevention against dengue virus infection
US20150196631A1 (en) * 2012-07-24 2015-07-16 Sanofi Pasteur Vaccine compositions
JP6818548B2 (ja) * 2013-03-15 2021-01-20 タケダ ワクチン, インコーポレイテッドTakeda Vaccines, Inc. ワクチンにおけるデングウイルスキメラ構築物に関する組成物および方法
TWI852899B (zh) 2014-09-02 2024-08-21 法商賽諾菲巴斯德公司 疫苗組合物
WO2017005652A1 (en) 2015-07-03 2017-01-12 Sanofi Pasteur Concomitant dengue and yellow fever vaccination
JP7313345B2 (ja) 2017-10-05 2023-07-24 サノフィ・パスツール デング熱に対するブースターワクチン接種のための組成物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0604566T3 (da) * 1991-09-19 2000-04-10 Us Health Kimærisk og/eller vækstbegrænsede flavivirus
ATE412738T1 (de) * 2000-05-30 2008-11-15 Univ Mahidol Attenuierte stammen von denguevirus und ihre verwendungen in impfstoffzusammensetzungen
MX2007015873A (es) * 2005-06-17 2008-04-22 Sanofi Pasteur Cepa atenuada de virus de dengue serotipo 1.

Also Published As

Publication number Publication date
JP2009523019A (ja) 2009-06-18
US8227587B2 (en) 2012-07-24
CA2633005C (en) 2014-12-09
CA2633005A1 (en) 2007-08-23
WO2007093472A1 (en) 2007-08-23
EP1974023B1 (en) 2013-12-18
US20100215692A1 (en) 2010-08-26
US20110206730A1 (en) 2011-08-25
EP1974023A1 (en) 2008-10-01
US7968102B2 (en) 2011-06-28

Similar Documents

Publication Publication Date Title
AR059005A1 (es) Virus quimericos del dengue
CL2011000136A1 (es) Compuestos derivados de 3-fenilpiridin-2-ona, inhibidores de rna polimerasa dependiente de rna viral; composicion faramceutica que comprende dichos compuestos; y su uso para el tratamiento de una enfermedad causada por el virus de la hepatitis c.
CL2009002207A1 (es) Compuestos derivados de 3-hidroxi-5-(9h-purin-9-il)tetrahidrofuran-2-il, inhibidor de la replicacion de arn viral dependiente de arn; composicion farmaceutica; uso para el tratamiento de hepatitis c.
CL2011002286A1 (es) Uso de compuestos derivados de nucleosidos para tratar una enfermedad viral; compuestos derivados de nucleosidos; y composicion farmaceutica que comprende los compuestos.
CL2016001580A1 (es) Uso de compuestos derivados de indol para tratar una infección por flavivirus; compuestos derivados de indol; composiciones farmacéuticas; y uso de una combinación.
CL2008003511A1 (es) Compuestos derivados nucleotidicos, inhibidores de polimerasa ns5b del virus de la hepatitis c; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de la hepatitis c.
ECSP099685A (es) Compuestos de azufre como inhibidores de la serina proteasa ns3 del virus de la hepatitis c
EA201491676A1 (ru) Партии рекомбинантного аденовируса с измененными концевыми областями
MX2012001916A (es) Uso combinado de trampas gdf y activadores de receptor de eritropoyetina para incrementar los niveles de globulos rojos.
JO3408B1 (ar) مركبات بترين سلفون اميد ثيازول و أوكسازول
CL2013003360A1 (es) “compuestos derivados de 4-aril-n-[3-(sulfonimidoil)fenil]-1,3,5-triazin-2-amina sustituidos, inhibidores cdk; compuestos intermediarios, composición y combinación farmacéutica que los comprende; y su uso en el tratamiento de enfermedades hiperproliferativas, infecciosas inducidas por virus y/o cardiovasculares”. pct
DOP2010000396A (es) Derivado de uracilo o timina para el tratamiento de hepatitis c
HN2011003195A (es) Modulares de gpr 119
BRPI0922364A2 (pt) Composto, composição farmacêutica e uso de um composto
CR20160418A (es) Nuevos compuestos biciclicos de 7 eslabones
UY34701A (es) Formas sólidas de un profármaco de nucleótidos de tiofosforamidato
BRPI0709266B8 (pt) 5-(hidroximetileno e aminometileno) pirimidinas substituídas e composição farmacêutica que as compreende
EA201200631A1 (ru) Ингибиторы репликации вируса иммунодефицита человека
UA108741C2 (uk) Фармацевтична композиція для екстреної контрацепції
GT201400111A (es) Triazolopiridinas sustituidas
CL2012001068A1 (es) Polinucleotido que codifica oleosina modificada incluyendo al menos una cisteina introducida artificialmente, constructo genetico que comprende dicho polinucleotido; célula huesped; composicion que comprende un cuerpo oleoso; alimento animal que comprende el cuerpo oleoso.
MX2009004862A (es) Estabilizacion de vacunas por liofilizacion.
EA200970916A1 (ru) Соединения 5,6-дигидро-1н-пиридин-2-она
EA201401193A1 (ru) Триарильные соединения и композиции, их содержащие
AR066395A1 (es) Reovirus que tienen secuencias modificadas

Legal Events

Date Code Title Description
FA Abandonment or withdrawal